Details of the Drug Combination

General Information of Drug Combination (ID: DCEPIN8)

Drug Combination Name
DFN-15 SY-1425
Indication
Disease Entry Status REF
High grade ovarian serous adenocarcinoma Investigative [1]
Component Drugs DFN-15   DM3BF9B SY-1425   DMH8UF0
N.A. N.A.
High-throughput Screening Result Testing Cell Line: OVCAR-4
Zero Interaction Potency (ZIP) Score: 1.66
Bliss Independence Score: 4.37
Loewe Additivity Score: 1.84
LHighest Single Agent (HSA) Score: 1.73

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of DFN-15
Disease Entry ICD 11 Status REF
Migraine 8A80 Phase 3 [2]
Indication(s) of SY-1425
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Phase 1 [3]
Myelodysplastic syndrome 2A37 Phase 1 [3]
SY-1425 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Retinoic acid receptor alpha (RARA) TTW38KT RARA_HUMAN Agonist [3]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Colon carcinoma DCGOOAU KM12 Investigative [4]
Invasive ductal carcinoma DCYZOEB HS 578T Investigative [4]
Amelanotic melanoma DCKFZ16 M14 Investigative [1]
Cutaneous melanoma DC53O5U SK-MEL-5 Investigative [1]
High grade ovarian serous adenocarcinoma DCBL4FV OVCAR-5 Investigative [1]
------------------------------------------------------------------------------------

References

1 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1126165